Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Study Title

A Phase 1, Single Dose, Parallel Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TV-44749, Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use, in Chinese Patients with Schizophrenia

Teva Identifier

TV44749-PK-10188

ClinicalTrials.gov Identifier

NCT06253546

Study Status

Recruiting

Trial Condition(s)

Schizophrenia

Interventions

Drug: TV-44749

Study Description

The primary objective is to evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia.
Click for participation criteria and map of study locations

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 64 Years

Trial Duration

March 28, 2024 - January 31, 2025

Phase

Phase 1

Study Type

Interventional